Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats

Hatice Aygün; Serdar Savaş Gül

doi:10.7197/223.vi.531824

EN TR

Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats

Abstract

Aim: Adriamycin (ADR) is an antineoplastic drug that is widely used in chemotherapy but its cardiotoxicity is the most important side effect that limits the clinical use of this drug. In this study, we investigated of edaravone (EDO), which is a potent antioxidant, ADR-induced cardiotoxicity model in rats by electrocardiographic (ECG), biochemical and scintigraphic methods.

Methods: Twenty-eight adult male Wistar-Albino rats were randomly separated into four groups; namely control (CON); Adriamycin (ADR); substance control of edaravone (EDO), edaravone + adriamycin (EDO+ADR) groups. Cardiotoxicity in rats was induced by adriamycin injection (cumulative dose:18 mg/kg, intraperitoneal-i.p.-) at an interval of 24 hours (h) on the 5^th, 6^th and 7^th days. Rats receiving edaravone treatment in the adriamycin group administration edaravone (30 mg/kg/day, i.p.) for 7 days and were injected with adriamycin (18 mg/kg, i.p.) on 5^th, 6^th and 7^th days. On the 8^th day electrocardiography (ECG), biochemical and technetium-99m pyrophosphate (^99mTc-PYP) scintigraphic parameters were assessed.

Results: ADR induction caused changes in the ECG pattern, decreased heartbeat, P wave and QRS complex duration, increased both ST-segment amplitude and QT interval duration (p < 0,001), increase in the biochemical markers [blood urea nitrogen (BUN), creatine kinase (CK), cardiac troponin T (cTnT)], and elevated ^99mTc-PYP uptake level (p < 0,001). EDO treatment prevented all the parameters of ADR-induced cardiotoxicity in rats, by significantly decreased all ADR-associated conduction abnormalities in ECG (p < 0.001), decreased ^99mTc-PYP uptake (p < 0.001) and serum BUN, CK and cTnT, (p < 0.001).

Conclusions: Our data demonstrate that EDO has cardioprotective effects on DOX-induced cardiotoxicity. At the same time, this study suggested that ^99mTc-PYP may be using as a non-invasive method for the early diagnosis of ADR-induced cardiotoxicity.

Keywords

Adriamycin,cardiotoxicity,edaravone,99mTc-PYP,ECG

References

Damiani RM, Moura DJ, Viau CM, et al. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016;90:2063-2076.
Wang L, Zhang X, Chan JY, et al. A novel danshensu derivative prevents cardiac dysfunction and improves the chemotherapeutic efficacy of doxorubicin in breast cancer cells. J Cell Biochem. 2016;117:94-105.
Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases, J Allergy Clin Immunol. 2008;122(3):574-580.
Cappetta D, Rossi F, Piegari E, et al. Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res. 2018;127:4-14.
Anjos Ferreira AL, Russell RM, Rocha N, et al. Effect of lycopene on doxorubicin-induced cardiotoxicity: an echocardiographic, histological and morphometrical assessment. Basic Clin Pharmacol Toxicol. 2007;101:16-24.
Swamy AH, Wangikar U, Koti BC, et al. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. Indian J Pharmacol. 2011;43(5):507-511.
Aygun H, Gul SS. Effects of melatonin and agomelatine on doxorubicin induced anxiety and depression-like behaviors in rats. Medical Science and Discovery. 2018;5(7):253-259.
Gül SS, Aygün H. Cardioprotective effect of vitamin D and melatonin on doxorubicin-induced cardiotoxicity in rat model: an electrocardiographic, scintigraphic and biochemical study. The European Res J. 2018. doi: 10.18621/eurj.410029.

Aygun H, Gul SS. Protective effect of melatonin and agomelatine on adriamycin-induced nephrotoxicity in rat model: a renal scintigraphy and biochemical study. Bratisl Med J. 2019;120(2):119-123.
The Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222-229.
Tokumaru O, Shuto Y, Ogata K, et al. Dose-dependency of multiple free radical-scavenging activity of edaravone. J Surg Res. 2018;228:147-153.
Abe S, Kirima K, Tsuchiya K, et al. The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin5-one (MCI-186)) with hydroxyl radical. Chem Pharm Bull. (Tokyo) 2004;52(2):186-191.
Suzuki J, Yanagisawa A, Shigeyama T, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999;50:37-45.
Koti BC, Nagathan S, Vishwanathswamy A, et al. Cardioprotective effect of Vedic Guard against doxorubicin-induced cardiotoxicity in rats: A biochemical, electrocardiographic, and histopathological study. Pharmacogn Mag. 2013;9:176-181.
Bhatt L, Joshi V. Mangifera indica L. leaf extract alleviates doxorubicin induced cardiac stress. J Intercult Ethnopharmacol. 2017;6:284-289.
Bilginoglu A, Aydın D, Ozsoy S, Aygün H. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyol Dern Ars 2014;42(3):265-273.
Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639-1642.
Renu K, Abilash VG, P B TP, et al. Molecular mechanism of doxorubicin-induced cardiomyopathy–An update. Eur J Pharmacol. 2018;818:241-253.
Xin Y, Zhan S, Gu L, et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol Pharm Bull. 2011;34(10):1523-1526.
Wang S, Konorev EA, Kotamraju S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem. 2004;279:25535-25543.
Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv. 2005;5(3):163-171.
Wakade AS, Shah AS, Kulkarni MP, Juvekar AR. Protective effect of Piper longum L. on oxidative stress induced injury and cellular abnormality in adriamycin induced cardiotoxicity in rats. Indian J Exp Biol. 2008;46:528-533.
Hassan MQ, Akhtar MS, Akhtar M, et al. Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. Ther Adv Cardiovasc Dis. 2016;10(4):214-223.
Kikuchi K, Tancharoen S, Takeshige N, et al. The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 2013;14(7):13909-13930.
Im GJ, Chang J, Lee S, et al. Protective role of edaravone against cisplatin-induced ototoxicity in an auditory cell line. Hear Res. 2015;330:113-118.
Mochizuki T, Murase K, Higashino H, et al. Ischemic "memory image" in acute myocardial infarction of 123I-BMIPP after reperfusion therapy: a comparison with 99mTc-pyrophosphate and 201Tl dual-isotope SPECT. Ann Nucl Med. 2002;16(8):563-568.
Einstein AJ, Shuryak I, Castano A, et al. Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018. doi: 10.1007/s12350-018-1307-7.
Isoda H, Itagaki Y, Nomura N, et al. Usefulness of dual SPECT with Tc-99m pyrophosphate and Tl-201 to predict further events after acute myocardial infarction with single-vessel coronary artery disease. Clin Nucl Med. 1999;24(4):227-231.
Okuda K, Nohara R, Fujita M, et al. Technetium-99m-pyrophosphate uptake as an indicator of myocardial injury without infarct. J Nucl Med 1994;35:1366-1370.
Affleck DG, Edelman L, Morris SE, Saffle JR. Assessment of tissue viability in complex extremity injuries: utility of the pyrophosphate nuclear scan. J Trauma. 2001;50:263-269.
Chang HR, Kao CH, Lian JD, et al. Evaluation of the severity of traumatic rhabdomyolysis using technetium-99m pyrophosphate scintigraphy. Am J Nephrol. 2001;21:208-214.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Hatice Aygün ^*
Türkiye

Serdar Savaş Gül
0000-0003-4822-2588
Türkiye

Publication Date

March 28, 2019

Submission Date

February 25, 2019

Acceptance Date

March 25, 2019

Published in Issue

Year 2019 Volume: 41 Number: 1

DOI

https://doi.org/10.7197/223.vi.531824

IZ

https://izlik.org/JA73UE77UN

Cite

RIS / Bibtex

AMA

1.Aygün H, Gül SS. Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats. CMJ. 2019;41(1):10-18. doi:10.7197/223.vi.531824

Cited By

Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [99mTc]DMSA renal scintigraphy and biochemical methods

Naunyn-Schmiedeberg's Archives of Pharmacology

https://doi.org/10.1007/s00210-020-01832-2

Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats

Abstract

Keywords

Öz

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite

Cited By

Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [99mTc]DMSA renal scintigraphy and biochemical methods